Lapatinib is not only a potent inhibitor of the HER2 but also inhibits EGFR tyrosine kinase domains and has shown significant clinical efficacy in non-IBC HER2+ breast cancer [54, 55]. This evidence concerns the gene ERBB2 and breast carcinoma.